<html>
<head>
<title>Clinical Evidence</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
</head>

<body bgcolor="#999999">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="000868" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><font color="#FFFFFF"><a name="Top"></a><img src="../Assets/ABMtitle.gif" width="660" height="50"></font></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="26" width="54"></td>
    <td valign="top" width="723" height="26"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_ABM.html"><img src="../Assets/CE1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_ABM.html"><img src="../Assets/CE2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_ABM.html"><img src="../Assets/CE3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_ABM.html"><img src="../Assets/CE4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_ABM.html"><img src="../Assets/CE5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_ABM.html"><img src="../Assets/CE6.gif" width="121" height="37" border="0"></a></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="44" width="54"></td>
    <td valign="top" height="44"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/CEheader.gif" width="330" height="50" align="baseline"><img src="../Assets/CEheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="746" height="469" bgcolor="ffffff"> 
            <div align="center"><br>
              <table width="90%" border="0">
                <tr bordercolordark="#ffffff" bordercolorlight="#c2c2c2"> 
                  <td class=heading id=heading> 
                    <script src="Alpha_blocker_Monotherapy_CE_content_files090601/0205_i16_files/0205_i16.0"></script>
                    <script language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </script>
                    <table width="100%" border=0>
                      <tbody> 
                      <tr> 
                        <td align=right><span class=localheadtopic 
            id=localheadtopic><section>Cardiovascular disorders</section></span><img height=10 
            src="Alpha_blocker_Monotherapy_CE_content_files090601/0205_i16_files/spacer.gif" width=10 align=absMiddle 
            border=0><br>
                          <span class=localhead id=localhead><topic>Primary prevention</topic><img height=10 src="Alpha_blocker_Monotherapy_CE_content_files090601/0205_i16_files/spacer.gif" 
            width=10 align=absMiddle border=0></span></td>
                      </tr>
                      <tr> 
                        <td class=title-author id=title-author valign=top noWrap align=right 
          bgcolor=#ffffff height=30><a 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=0205_CONTRIB&amp;t=document-frame.htm&amp;2.0&amp;p="><em>Clinical 
                          Evidence</em> writers on primary prevention</a><img height=10 
            src="Alpha_blocker_Monotherapy_CE_content_files090601/0205_i16_files/spacer.gif" width=10 align=absMiddle 
        border=0></td>
                      </tr>
                      </tbody>
                    </table>
                    <br>
                    <h1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Antihypertensive 
                      drugs</h1>
                    <table cellspacing=0 cellpadding=3 width="100%" border=0>
                      <tbody> 
                      <tr> 
                        <td class=question id=question valign=top width="10%" bgcolor="#333333"><b><span 
            class=question-title id=question-title><font color="#FFFFFF">QUESTION</font></span></b></td>
                        <td class=question id=question bgcolor="#CCCCCC">&nbsp;<b>What 
                          are the effects of drug treatment in primary hypertension?</b></td>
                      </tr>
                      </tbody>
                    </table>
                    <br>
                    <a 
      name=I16> 
                    <h2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden"><font color="#000099">Comparing 
                      antihypertensives</font></h2>
                    <table cellspacing=0 cellpadding=0 width="100%" border=0>
                      <tbody> 
                      <tr class=option id=option> 
                        <td class=option id=option style="PADDING-LEFT: 2px" valign=top 
          width="10%" bgcolor="#000099"><span class=option-title 
            id=option-title><font color="#FFFFFF">OPTION</font>&nbsp;&nbsp;&nbsp;</span></td>
                        <td class=option id=option style="PADDING-LEFT: 2px" 
            width="100%" bgcolor="#CCCCFF"><b>Comparing antihypertensive drug 
                          treatments</b></td>
                      </tr>
                      </tbody>
                    </table>
                    </a> 
                    <table cellspacing=0 cellpadding=0 width="100%" border=0>
                      <tbody> 
                      <tr> 
                        <td><a name=I16-SUMSTATEMENT><b> 
                          <p style="MARGIN-LEFT: 3px" align=justify>Two systematic 
                            reviews have found that initial treatment with diuretics, 
                            ACE inhibitors, or ß blockers reduces mortality and 
                            morbidity, with minimal adverse effects. RCTs found 
                            no significant morbidity or mortality differences 
                            among these agents. We found limited evidence from 
                            one systematic review of RCTs that diuretics, ß blockers, 
                            and ACE inhibitors reduced coronary heart disease 
                            and heart failure more than calcium channel antagonists. 
                            One RCT has found that a thiazide diuretic is superior 
                            to an &#945; blocker in reducing cardiovascular events, 
                            particularly congestive heart failure.</p>
                          </b></a></td>
                      </tr>
                      </tbody>
                    </table>
                    <br>
                    <table cellspacing=0 cellpadding=3 width="100%" border=0>
                      <tbody> 
                      <tr> 
                        <td> 
                          <p align=justify><font color=#0033cc><a 
            name=I16-BENEFITS><b>Benefits: </b></a></font><b>ß Blockers versus 
                            diuretics: </b>One systematic review (search date 
                            1995, &gt;&nbsp;48&nbsp;000 people) identified RCTs 
                            comparing effects of high and low dose diuretics versus 
                            ß blockers. <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF128">[128]</a> 
                            A second systematic review (search date 1998) was 
                            limited to 10 RCTs in 16&nbsp;164 elderly people. 
                            <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF129">[129]</a> 
                            These reviews did not summarise direct comparisons 
                            of diuretics versus ß blockers but compared results 
                            of trials that used diuretics as first line agents 
                            versus results of trials that used ß blockers as first 
                            line agents. The reviews found no significant difference 
                            between diuretics and ß blockers for lowering blood 
                            pressure. They found that diuretics reduced coronary 
                            events, but found no evidence that ß blockers reduced 
                            coronary events. <b>ß Blockers versus ACE inhibitors: 
                            </b>One single blind RCT (10&nbsp;985 people, aged 
                            25–66 years) found that an ACE inhibitor (captopril) 
                            was no more effective than conventional treatment 
                            (diuretics or ß blockers) in reducing cardiovascular 
                            morbidity or mortality. Captopril increased the risk 
                            of stroke compared with ß blockers (125 people would 
                            need to be treated with ACE inhibitor rather than 
                            ß blocker for one extra stroke to occur, 95% CI 69 
                            to 651 people). However, the methods of the trial 
                            may limit the validity of results (see comment below). 
                            <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF130">[130]</a> 
                            <b>Comparison of ß blockers, diuretics, ACE inhibitors, 
                            and calcium channel antagonists: </b>One unblinded 
                            RCT (6600 people, aged 70–84 years) compared diuretics, 
                            ß blockers, or both, versus calcium channel antagonists 
                            (felodipine or isradipine) versus ACE inhibitors (enalapril 
                            or lisinopril). It found no significant difference 
                            in blood pressure control or cardiovascular morbidity 
                            or mortality. <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF131">[131]</a> 
                            One systematic review (search date 2000, 8 RCTs) compared 
                            different antihypertensive regimens, and found no 
                            significant differences in outcome among people initially 
                            treated with ß blockers, diuretics, or ACE inhibitors. 
                            <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF132">[132]</a> 
                            However, it found that ß blockers or diuretics decreased 
                            coronary events compared with calcium channel antagonists, 
                            and increased stroke rate, although there was no significant 
                            difference for all cause mortality (OR for mortality, 
                            ß blockers or diuretics <em>v</em> calcium antagonists 
                            1.01, 95% CI 0.92 to 1.11). ACE inhibitors did not 
                            significantly alter all cause mortality or stroke 
                            rate compared with calcium channel antagonists, but 
                            decreased coronary events (OR for ACE inhibitor <em>v</em> 
                            calcium antagonist 1.03, 95% CI 0.91 to 1.18 for all 
                            cause mortality; 1.02, 95% CI 0.85 to 1.21 for stroke; 
                            0.81, 95% CI 0.68 to 0.97 for coronary events). <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF132">[132]</a> 
                            <b><font color="#FF0000">Comparison of &#945; blockers 
                            and diuretics:</font></b><font color="#FF0000"> A 
                            double blind RCT (335 high risk people with hypertension) 
                            found no differences in coronary heart disease outcomes 
                            between doxazosin, an &#945; blocker, compared with 
                            chlortalidone. However, doxazosin compared with chlortalidone 
                            increased the total number of cardiovascular events 
                            (4 year rate 25% <em>v</em> 22%; HR 1.25, 95% CI 1.17 
                            to 1.33) and, in particular, increased congestive 
                            heart failure (4 year rate 8% <em>v</em> 4%; HR 2.04, 
                            95% CI 1.79 to 2.32). <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF133">[133]</a> 
                            </font><b>Drug treatment in people with diabetes: 
                            </b><a 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=0601&amp;t=document-frame.htm&amp;2.0&amp;p=">See 
                            cardiovascular disease in diabetes</a>.</p>
                        </td>
                      </tr>
                      </tbody>
                    </table>
                    <table cellspacing=0 cellpadding=3 width="100%" border=0>
                      <tbody> 
                      <tr> 
                        <td> 
                          <p align=justify><font color=#0033cc><a name=I16-HARMS><b>Harms: 
                            </b></a></font><b>Quality of life and tolerability:</b> 
                            In the three long term, double blind comparisons of 
                            low dose diuretics, ß blockers, ACE inhibitors, and 
                            calcium channel blockers, tolerability and overall 
                            quality of life indicators tended to be more favourable 
                            for diuretics and ß blockers than for newer drugs. 
                            <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF134">[134]</a> 
                            <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF135">[135]</a> 
                            <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF136">[136]</a> 
                            One systematic review (search date 1998) of RCTs comparing 
                            thiazides versus ß blockers found that thiazides were 
                            associated with fewer withdrawals because of adverse 
                            effects (RR 0.69, 95% CI 0.63 to 0.76). <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF137">[137]</a> 
                            Adverse effects are agent specific. The recent unblinded 
                            RCT comparing diuretics, ß blockers, calcium channel 
                            antagonists, and ACE inhibitors found that after 5 
                            years of follow up, 26% of people receiving felodipine 
                            or isradipine reported ankle oedema, 30% receiving 
                            enalapril or lisonopril reported cough, and 9% receiving 
                            diuretics and/or ß blockers reported cold hands and 
                            feet. <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF131">[131]</a> 
                            <b>Major harm controversies:</b> Case control, cohort, 
                            and randomised studies suggest that short and intermediate 
                            acting dihydropyridine calcium channel blockers, such 
                            as nifedipine and isradipine, may increase cardiovascular 
                            morbidity and mortality. <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF138">[138]</a> 
                          </p>
                        </td>
                      </tr>
                      </tbody>
                    </table>
                    <table cellspacing=0 cellpadding=3 width="100%" border=0>
                      <tbody> 
                      <tr> 
                        <td> 
                          <p align=justify><font color=#0033cc><a name=I16-COMMENT><b>Comment: 
                            </b></a></font>Results of the large ACE inhibitor 
                            trial reported above warrant cautious interpretation 
                            because a flaw in the randomisation process resulted 
                            in unbalanced groups. <a 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?fn=document-frame.htm&amp;f=templates#REF130">[130]</a> 
                          </p>
                        </td>
                      </tr>
                      </tbody>
                    </table>
                    <br>
                    <a name=references></a> 
                    <table cellspacing=0 cellpadding=0 border=0>
                      <tbody> 
                      <tr> 
                        <td width=90 bgcolor=#404040><img height=2 src="" width=1 
            align=absMiddle border=0></td>
                        <td valign=bottom width="100%" bgcolor=#404040><img height=2 src="" 
            width=1 align=absMiddle border=0></td>
                      </tr>
                      <tr> 
                          <td class=key-message id=key-message width=90 
            bgcolor=#CCCCCC><b>References</b></td>
                        <td width="100%">&nbsp;</td>
                      </tr>
                      </tbody>
                    </table>
                    <br>
                    <table cellpadding=2 width="100%" align=center>
                      <tbody> 
                      <tr><a class=reference id=reference name=REF128></a> 
                        <td class=reference id=reference valign=top width=15>128. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Psaty 
                          BM, Smith NS, Siscovick DS, et al. Health outcomes associated 
                          with antihypertensive therapies used as first line agents: 
                          a systematic review and meta-analysis. <em>JAMA</em> 
                          1997;277:739–745. Search date 1995; primary source Medline. 
                          <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=97195474");' style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      <tr><a class=reference id=reference name=REF129></a> 
                        <td class=reference id=reference valign=top width=15>129. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Messerli 
                          FH, Grossman E, Goldbourt. Are beta blockers efficacious 
                          as first-line therapy for hypertension in the elderly? 
                          A systematic review. <em>JAMA</em> 1998;279:1903–1907. 
                          Search date 1998; primary source Medline. <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=98296020");' style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      <tr><a class=reference id=reference name=REF130></a> 
                        <td class=reference id=reference valign=top width=15>130. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Hansson 
                          L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme 
                          inhibition compared with conventional therapy on cardiovascular 
                          morbidity and mortality in hypertension: the captopril 
                          prevention project (CAPP) randomised trial. <em>Lancet</em> 
                          1999;353:611–616. <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=99153396");' style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      <tr><a class=reference id=reference name=REF131></a> 
                        <td class=reference id=reference valign=top width=15>131. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Hansson 
                          L, Lindholm L, Ekbom T, et al. Randomised trial of old 
                          and new antihypertensive drugs in elderly patients: 
                          cardiovascular mortality and morbidity the Swedish trial 
                          in old patients with hypertension-2 study. <em>Lancet</em> 
                          1999;354:1751–1756. <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20043567");' style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      <tr><a class=reference id=reference name=REF132></a> 
                        <td class=reference id=reference valign=top width=15>132. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Blood 
                          Pressure Lowering Treatment Trialists' Collaboration. 
                          Effects of ACE inhibitors, calcium antagonists, and 
                          other blood-pressure-lowering drugs: results of prospectively 
                          designed overviews of trials. <em>Lancet</em> 2000;356:1955–1964. 
                          Search date July 2000; primary sources WHO-International 
                          Society of Hypertension registry of randomised trials; 
                          trials were sought that had not published or presented 
                          their results before July 1995. <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21012986");' style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      <tr><a class=reference id=reference name=REF133></a> 
                        <td class=reference id=reference valign=top width=15>133. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">The 
                          ALLHAT Officers and Coordinators for the ALLHAT Collaborative 
                          Research Group. Major cardiovascular events in hypertensive 
                          patients randomized to doxazosin vs chlorthalidone: 
                          the antihypertensive and lipid-lowering treatment to 
                          prevent heart attack trial (ALLHAT). <em>JAMA</em> 2000;283:1967–1975. 
                          <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20248526");' style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      <tr><a class=reference id=reference name=REF134></a> 
                        <td class=reference id=reference valign=top width=15>134. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Neaton 
                          JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension 
                          study: final results. <em>JAMA</em> 1993;270:713–724. 
                          <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=93329754");' 
            style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      <tr><a class=reference id=reference name=REF135></a> 
                        <td class=reference id=reference valign=top width=15>135. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Materson 
                          BJ, Reda DJ, Cushman WC, et al. Single drug therapy 
                          for hypertension in men. <em>N Engl J Med</em> 1993;328:914–921. 
                          <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=93188917");' 
            style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      <tr><a class=reference id=reference name=REF136></a> 
                        <td class=reference id=reference valign=top width=15>136. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Philipp 
                          T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek 
                          S. Randomised, double blind, multicentre comparison 
                          of hydrochlorothiazide, atenolol, nitrendipine, and 
                          enalapril in antihypertensive treatment: results of 
                          the HANE study. <em>BMJ</em> 1997;315:154–159. <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=97395406");' 
            style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      <tr><a class=reference id=reference name=REF137></a> 
                        <td class=reference id=reference valign=top width=15>137. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Wright 
                          JM, Lee CH, Chambers CK. Systematic review of antihypertensive 
                          therapies: does the evidence assist in choosing a first 
                          line drug? <em>Can Med Assoc J</em> 1999;161:25–32. 
                          Search date 1998; primary sources Medline 1996 to 1997, 
                          Cochrane Library to 1998.</td>
                      </tr>
                      <tr><a class=reference id=reference name=REF138></a> 
                        <td class=reference id=reference valign=top width=15>138. 
                        </td>
                        <td class=reference id=reference valign=top width="100%">Cutler 
                          JA. Calcium channel blockers for hypertension&nbsp;—&nbsp;uncertainty 
                          continues. <em>N Engl J Med</em> 1998;338:679–680. <a 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=98135525");' 
            style="FONT-SIZE: 8pt">[PubMed]</a></td>
                      </tr>
                      </tbody>
                    </table>
                    <table width="100%" border=0>
                      <tbody> 
                      <tr> 
                        <td valign=bottom width="50%"> 
                          
                        <td align=right width="50%"><img 
            alt="BMJ - Clinical Evidence" src="../Assets/ce-pagebrand.jpg" 
            border=0 width="89" height="44"></td>
                      </tr>
                      <tr> 
                        <td align=left width="50%"> 
                        <td align=right width="50%"><a 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><span 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing Group</span></a></td>
                      </tr>
                      </tbody>
                    </table>
                    <script language=JavaScript>
			var purl = "0205.PDF"; 
</script>
                    <script language=JavaScript src="../Assets/stats.js" 
      type=text/javascript></script>
                    <script language=JavaScript type=text/javascript><!--
  stats("MC-MTg0OQ==-45MT-Y2Nz","","","");
//--></script>
                    <noscript><img height=1 src="" width=1 
  border=0></noscript></td>
                </tr>
                <tr> 
                  <td>
                    <div align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></div>
                  </td>
                </tr>
              </table>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="28" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="#3333FF"> 
            
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
